0.7062
price down icon5.46%   -0.0408
after-market After Hours: .73 0.0238 +3.37%
loading

Jaguar Health Inc Stock (JAGX) Latest News

pulisher
Feb 24, 2025

Jaguar Health Stock Plummets to 52-Week Low of $0.78 By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

Jaguar Health Stock Plummets to 52-Week Low of $0.78 - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Form DEF 14A Jaguar Health, Inc. For: Mar 13 - StreetInsider.com

Feb 24, 2025
pulisher
Feb 20, 2025

Jaguar Health extends debt maturity to 2026 By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Jaguar Health extends debt maturity to 2026 - Investing.com India

Feb 20, 2025
pulisher
Feb 19, 2025

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease StudyShort Bowel Syndrome with Intestinal Failure (SBS-IF) - Yahoo Finance

Feb 19, 2025
pulisher
Feb 19, 2025

Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges - MSN

Feb 19, 2025
pulisher
Feb 18, 2025

Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern - ACCESS Newswire

Feb 18, 2025
pulisher
Feb 18, 2025

Jaguar Health extends collaboration with Streeterville - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Jaguar Health advances cholera treatment, eyes FDA voucher - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Jaguar Health extends collaboration with Streeterville to develop P-300 - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Jaguar Health advances cholera treatment, eyes FDA voucher By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 - ACCESS Newswire

Feb 18, 2025
pulisher
Feb 18, 2025

Jaguar Health's Cholera Drug Could Unlock $350M FDA Voucher as WHO Declares Emergency - StockTitan

Feb 18, 2025
pulisher
Feb 16, 2025

Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website - ACCESS Newswire

Feb 16, 2025
pulisher
Feb 14, 2025

Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates - ACCESS Newswire

Feb 14, 2025
pulisher
Feb 13, 2025

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - WSIL TV

Feb 13, 2025
pulisher
Feb 13, 2025

Exclusive Investor Presentation: Jaguar Health CEO Reveals Strategic Roadmap and Growth Catalysts - StockTitan

Feb 13, 2025
pulisher
Feb 10, 2025

Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote - ACCESS Newswire

Feb 10, 2025
pulisher
Feb 08, 2025

Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020 - ACCESS Newswire

Feb 08, 2025
pulisher
Feb 08, 2025

Jaguar Health Provides Updates Regarding Company Capitalization Strategy - ACCESS Newswire

Feb 08, 2025
pulisher
Feb 07, 2025

Jaguar Health to Present at Biotech Showcase 2019 in San Francisco - ACCESS Newswire

Feb 07, 2025
pulisher
Feb 06, 2025

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference - Huntsville Item

Feb 06, 2025
pulisher
Feb 06, 2025

Breakthrough Plant-Based Drug Takes Aim at $38B ADHD & Schizophrenia Markets - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30% - Simply Wall St

Feb 05, 2025
pulisher
Feb 04, 2025

Jaguar Health extends loan maturity, issues stock for royalty interest reduction - MSN

Feb 04, 2025
pulisher
Feb 03, 2025

JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Jaguar Health announces first SBS-IF patient dosed in IIT trial of crofelemer - TipRanks

Feb 03, 2025
pulisher
Feb 03, 2025

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 - Yahoo Finance

Feb 03, 2025
pulisher
Feb 03, 2025

Rare Disease Breakthrough: First SBS-IF Patient Dosed in Groundbreaking Pediatric Trial - StockTitan

Feb 03, 2025
pulisher
Feb 01, 2025

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting - ACCESS Newswire

Feb 01, 2025
pulisher
Jan 31, 2025

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire

Jan 31, 2025
pulisher
Jan 29, 2025

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 29, 2025

This Drug Could Fix The Biggest Problem With Ozempic and Wegovy - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

Jaguar Health Provides Corporate Update and Outlines 2022 Milestones - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 29, 2025

Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 29, 2025

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 28, 2025

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 27, 2025

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ COVID-19 Recovery Patients in Europe - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Jaguar Health Appoints Carol Lizak Chief Accounting Officer - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 26, 2025

Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer" - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 24, 2025

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patien - ACCESS Newswire

Jan 24, 2025
$74.40
price up icon 0.53%
$22.96
price up icon 2.04%
$33.69
price down icon 0.33%
$357.50
price down icon 0.20%
$110.97
price down icon 5.14%
biotechnology ONC
$259.70
price up icon 0.47%
Cap:     |  Volume (24h):